In 2018, scientist He Jiankui stunned the world from a conference stage in Hong Kong. He announced he had created the world’s first gene-edited babies in 2018 [1], infants whose genetic material was intentionally altered at the embryonic stage to introduce specific traits. By modifying their genomes – the complete set of genetic instructions in an organism – he had made a change that was not only permanent but also heritable, meaning it could be passed down through all subsequent generations. The backlash was immediate and absolute. Global condemnation was followed by a three-year prison sentence in his native China. But following his release in 2022, He has returned to science, unrepentant and with a new, equally audacious goal: editing human embryos to prevent Alzheimer’s disease. This sets the stage for a profound conflict: a scientist who sees himself as a pioneer against a world grappling with the ethical lines he is determined to cross once more.
The Phoenix Project: He Jiankui’s New Alzheimer’s Gambit
Undeterred by his prison sentence and the global condemnation that followed, He Jiankui has embarked on a new, equally audacious venture from his recently established independent lab in Beijing. His goal is no less than the eradication of Alzheimer’s disease, not by treating existing patients, but by genetically engineering human embryos to be immune from the start. This new focus represents a defiant continuation of his work, shifting from HIV resistance to one of the most feared neurodegenerative disorders of our time.
The scientific foundation of his project rests on a specific genetic mutation, APP-A673T, first identified in an Icelandic population. Individuals carrying this mutation exhibit a natural, lifelong resistance to Alzheimer’s. He’s plan is to replicate this protection by introducing the mutation into embryos through germline editing. So, what is germline editing? It is a type of gene editing that makes changes to the DNA in reproductive cells or early embryos. This raises a complex debate around germline editing pros and cons. The critical and controversial aspect of this technique is that these changes are permanent and can be passed down to future generations, making it highly controversial due to its irreversible and inheritable nature.
For now, He claims his work remains within legal bounds. He asserts that research in his Beijing lab is confined to preliminary experiments on human cell lines and animal models. He has successfully secured significant private funding for this endeavor, having already raised $7 million from donors. He is actively seeking an additional $10 million to advance the project through comprehensive animal trials, a necessary step before any potential human application.
He’s justification for this new gambit leans heavily on the purported success of his first experiment. He repeatedly claims, without providing independent verification, that the three gene-edited girls born in 2018 are ‘healthy’ and ‘normal’ after several years. He views this as sufficient proof-of-concept to proceed on a much larger scale. His motivation appears unwavering, fueled by a conviction that his work is not just beneficial but revolutionary. When asked why he focuses on embryo editing over other therapies, his answer is simple and grandiose: ‘Because it is going to change the world.’ This statement encapsulates the immense ambition – and the profound ethical questions – at the heart of his phoenix project.
The Global Loophole Strategy: Bypassing Bans and Borders
With the door to human trials firmly shut in China, and varying gene editing laws around the world, He Jiankui has devised an international strategy to circumvent the ban on germline editing. His plan is a calculated, two-stage operation designed to navigate the global patchwork of laws and ethics. The initial, less controversial preclinical work – experiments on human cell lines, mice, and monkey embryos – will take place in his Beijing lab. Once this foundational research is complete, He intends to export the project, seeking a more permissive regulatory environment to conduct the pivotal human trials. He has been transparent about his search for a suitable host nation, publicly floating Hong Kong as a possibility and expressing a willingness to move the work to the United States or Japan, should their regulations ever allow for it. However, he has spoken most confidently about South Africa, claiming to have already engaged with individuals there who have shown “great interest” in his work. This assertion, however, collides with recent regulatory shifts. Contrary to his belief that the country has become more permissive, recent changes to South Africa’s gene editing legislation saw the removal of language from its national ethics guidelines in August 2025 that some interpreted as potentially allowing heritable human genome editing [3]. This move effectively tightened, rather than loosened, its stance, casting significant doubt on the viability of his South African ambitions. But He’s strategy is not just about finding a new location; it’s about radically expanding the scope of his original experiment. His current focus on an Alzheimer’s-preventing mutation is merely a stepping stone. The ultimate vision, which he is actively developing in his lab, is to move beyond single-gene corrections. He envisions a future where human embryos receive a comprehensive panel of 10 to 20 genetic edits simultaneously. This ambitious procedure would aim to prevent not just one condition, but a whole spectrum of major human diseases, including cancer, HIV, and cardiovascular ailments. The goal is no longer just to fix a potential vulnerability but to engineer fundamentally healthier children who may live longer than any generation before them – a breathtaking leap that redefines the very purpose of his controversial science.
The Counter-Narrative: Unverified Claims and Ethical Blind Spots
While He Jiankui casts himself as a misunderstood visionary, a closer examination of his claims reveals a narrative riddled with inconsistencies and profound ethical blind spots. The image of the ‘pioneer’ he cultivates in interviews stands in stark contrast to the unverified nature of his work and his open dismissal of the very frameworks designed to prevent scientific overreach.
The cornerstone of his defense is the assertion that the world’s first gene-edited children are ‘healthy and normal.’ This critical claim, however, remains entirely his own, lacking any independent, peer-reviewed scientific validation. Without external verification, his assurances are anecdotal at best, potentially masking a host of long-term, unforeseen health consequences. The global scientific community remains deeply concerned about the inherent gene editing risks, such as off-target mutations and genetic mosaicism – complex issues that cannot be waved away by early childhood observation.
He’s self-proclaimed transparency is equally questionable. While he actively uses social media to project an image of openness, this performance is contradicted by a conspicuous lack of verifiable data. He has yet to publish any results from his Duchenne muscular dystrophy research, leaving his claims of progress in a scientific black box. Furthermore, his Beijing lab, once touted as ‘open,’ is now closed to foreigners, effectively shielding his current work from international scrutiny and raising serious questions about accountability.
This posture seems less an oversight and more a feature of a defiant worldview. His mindset is perhaps best captured in a social media update where He Jiankui posted an image with the text “I did not violate ethics, I overturned it.” [2]. This is not the statement of a scientist seeking to engage with ethical debate, but of one who has unilaterally decided to operate outside of it.
This perspective underpins his core philosophy: that ‘patient happiness‘ trumps all other concerns. When considering designer babies, medical ethics are paramount, yet this dangerously simplistic maxim demonstrates a profound disregard for established bioethical principles built over decades. It ignores the societal consensus that recognizes the potential for harm extends far beyond a single patient to future generations and the human gene pool itself.
Finally, the question of funding casts a long shadow over his motives. Despite his denials, the substantial private funding he has secured from anonymous donors invites a critical counter-thesis: that this financial backing could be driven by wealthy individuals seeking genetic enhancement for their own offspring. This creates a glaring conflict of interest, where the research agenda may be dictated not by broad societal benefit but by the bespoke desires of a privileged few.
Pandora’s Box: The Global Risks of Heritable Gene Editing
While the actions and ambitions of He Jiankui are a compelling narrative, focusing solely on the individual misses the far greater danger he represents. His work did not just break laws and ethical norms; it opened a Pandora’s Box of global risks that now cannot be easily closed. The true challenge lies in confronting the profound societal, medical, and geopolitical consequences that unregulated heritable gene editing has unleashed upon the world.
The most immediate and visceral of these is the ethical risk. The technology raises significant designer babies ethical concerns, paving a direct path toward the creation of “designer babies,” where genetic traits could be selected or enhanced based on parental preference and financial means. The ethics of genetic engineering for designer babies are deeply troubling, as this raises the specter of a new, technologically-driven eugenics, capable of exacerbating social inequalities to a degree never before seen and fundamentally redefining what it means to be human. Closely tied to this is the long-term health risk. Making permanent, heritable alterations to the human genome introduces significant gene editing health risks. Any unforeseen consequences – subtle mutations, unexpected diseases, or developmental problems – would not only affect the individual but would be passed down through all subsequent generations, irrevocably altering family lineages with potentially severe health outcomes.
On a global scale, the regulatory risk is immense. He’s stated interest in conducting trials in countries with more permissive laws highlights the danger of creating “ethics havens.” Such jurisdictions could attract researchers and funding aimed at circumventing international consensus, leading to a global race to the bottom in bioethical standards. This, in turn, creates a significant geopolitical risk. When citizens or institutions of one nation conduct research deemed illegal and unethical by others, it can easily ignite international tensions and diplomatic conflicts, especially when the consequences affect the shared human gene pool.
Ultimately, these factors culminate in a profound social risk: the erosion of public trust in science and medicine. Controversial human experimentation, especially when it appears to lack accountability, can poison the relationship between the scientific community and the society it serves. He Jiankui’s case is more than a cautionary tale; it is a global alarm forcing us to grapple with the immense responsibility that comes with the power to rewrite our own evolution.
A Crossroads for Humanity
He Jiankui’s resurgence is not merely a continuation of his controversial work; it is a deliberate escalation that forces a global reckoning many had hoped was still years away. His actions crystallize the profound conflict of our age: the noble ambition to eradicate devastating diseases set against the immense, irreversible risks of altering the human germline. This is no longer a theoretical debate. His unwavering pursuit places humanity at a critical crossroads, staring down three starkly different futures. In the most optimistic outcome, He successfully demonstrates the safety and efficacy of germline editing for preventing severe genetic diseases like Alzheimer’s in a regulated international setting, leading to a new era of responsible therapeutic gene editing. A more stagnant, neutral state would see him continue his research in a legally ambiguous ‘ethics haven,’ making incremental scientific progress while facing perpetual global condemnation. The most frightening possibility highlights the severe germline editing problems: a negative catastrophe where He proceeds with human embryo editing in an unregulated environment, resulting in severe, unforeseen health complications for the children, triggering a global moratorium on all germline editing research and further eroding public trust in science. Regardless of his intent, He’s work has dragged the conversation from academic halls into reality. The question is no longer if we should wield this power, but how we will define its limits and whether we are prepared to rewrite our own evolutionary story.
Frequently asked questions
What is He Jiankui’s new scientific goal after his release from prison?
After his release in 2022, He Jiankui’s new audacious goal is to edit human embryos to prevent Alzheimer’s disease. He aims to genetically engineer human embryos to be immune from the start, rather than treating existing patients. This represents a defiant continuation of his work, shifting from HIV resistance to one of the most feared neurodegenerative disorders.
How does He Jiankui plan to prevent Alzheimer’s disease through gene editing?
He Jiankui plans to prevent Alzheimer’s by introducing a specific genetic mutation, APP-A673T, into embryos through germline editing. This mutation, first identified in an Icelandic population, confers natural, lifelong resistance to Alzheimer’s. His project aims to replicate this protection by making permanent, heritable changes to the DNA in early embryos.
Why is germline editing considered highly controversial according to the article?
Germline editing is highly controversial because it makes changes to the DNA in reproductive cells or early embryos that are permanent and can be passed down to future generations. This irreversible and inheritable nature raises profound ethical questions. The global scientific community is concerned about inherent risks like off-target mutations and genetic mosaicism, which could have unforeseen long-term health consequences.
Where does He Jiankui intend to conduct human trials for his gene-editing project?
He Jiankui intends to conduct preclinical work in his Beijing lab and then export the project to a more permissive regulatory environment for human trials. He has publicly floated Hong Kong as a possibility and expressed willingness to move to the United States or Japan. He has spoken most confidently about South Africa, despite recent regulatory changes there that tightened its stance on heritable human genome editing.
What are the main ethical and health risks associated with heritable human gene editing, as discussed in the article?
The article discusses significant ethical risks, including the creation of ‘designer babies’ and a new, technologically-driven eugenics that could exacerbate social inequalities. Long-term health risks involve unforeseen consequences like subtle mutations, unexpected diseases, or developmental problems that would be passed down through all subsequent generations. These issues raise concerns about irrevocably altering family lineages and the human gene pool.
